Events
New research shows benefits of exercise for first time in advanced lung cancer
- ESMO 2018: Erlotinib improves progression-free survival in early mutated non-small cell lung cancer
- Study shows surgery and radiation extend survival of patients with limited metastatic lung cancer
- CHMP announched positive opinion for brigatinib as treatment of ALK positive NSCLC in patients previously treated with crizotinib
Celebrating ANZUP Cancer Trials Group’s 10th anniversary
The Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group held its 7th standalone Annual Scientific Meeting (ASM)…










